Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBITDA Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBITDA Margin for 16 consecutive years, with 0.89% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 7587.0% to 0.89% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.03%, a 3630.0% increase, with the full-year FY2025 number at 8.03%, up 3970.0% from a year prior.
  • EBITDA Margin was 0.89% for Q4 2025 at Anika Therapeutics, up from 9.03% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2151.74% in Q4 2023 to a low of 75.36% in Q3 2024.
  • A 5-year average of 100.83% and a median of 9.16% in 2025 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 201346bps in 2023, then crashed -222673bps in 2024.
  • Anika Therapeutics' EBITDA Margin stood at 17.29% in 2021, then skyrocketed by 900bps to 138.28% in 2022, then surged by 1456bps to 2151.74% in 2023, then tumbled by -103bps to 74.99% in 2024, then skyrocketed by 101bps to 0.89% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's EBITDA Margin are 0.89% (Q4 2025), 9.03% (Q3 2025), and 9.29% (Q2 2025).